Clinical Cancer Research Prevention Award AACR Membership
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tanaka, Y.
Right arrow Articles by Nakano, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tanaka, Y.
Right arrow Articles by Nakano, H.
Clinical Cancer Research Vol. 11, 4783-4792, July 1, 2005
© 2005 American Association for Cancer Research

Imaging, Diagnosis, Prognosis

Clinical Significance of Heparin-Binding Epidermal Growth Factor–Like Growth Factor and A Disintegrin and Metalloprotease 17 Expression in Human Ovarian Cancer

Yoshihiro Tanaka1, Shingo Miyamoto1, Satoshi O. Suzuki2, Eiji Oki3, Hiroshi Yagi1, Kenzo Sonoda1, Ayano Yamazaki4, Hiroto Mizushima4, Yoshihiko Maehara3, Eisuke Mekada4 and Hitoo Nakano1

Authors' Affiliations: Departments of 1 Obstetrics and Gynecology, 2 Neuropathology, 3 Surgery and Sciences, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan and 4 Department of Cell Biology, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan

Requests for reprints: Shingo Miyamoto, Department of Obstetrics and Gynecology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan. Phone: 81-92-642-5395; Fax: 81-92-642-5414; E-mail: smiya{at}med.kyushu-u.ac.jp.


   Abstract
Top
 Abstract
Materials and Methods
 Results
 Discussion
 References
 
Purpose: Lysophosphatidic acid, which is enriched in the peritoneal fluid of ovarian cancer patients, plays a key role in the progression of ovarian cancer. Lysophosphatidic acid can generate epidermal growth factor receptor (EGFR) signal transactivation involving processing of EGFR ligands by ADAM (a disintegrin and metalloprotease) family metalloproteases. We aimed to investigate the clinical significance of EGFR ligands and ADAM family in the lysophosphatidic acid–induced pathogenesis of ovarian cancer.

Experimental Design: We examined the expression of EGFR ligands and ADAM family members in 108 patients with normal ovaries or ovarian cancer, using real-time PCR, immunohistochemistry, and in situ hybridization, and analyzed the clinical roles of these molecules. Statistical analyses of these data were done using the Mann-Whitney test, Kaplan-Meier method, or Spearman's correlation analysis.

Results: Large differences in expression were found for heparin-binding EGF-like growth factor (HB-EGF) and other EGFR ligands and for ADAM 17 and other ADAM family members. HB-EGF expression was significantly increased in advanced ovarian cancer compared with that in normal ovaries (P < 0.01). HB-EGF expression was significantly associated with the clinical outcome (P < 0.01). ADAM 17 expression was significantly enhanced in both early and advanced ovarian cancer compared with that in normal ovaries (both P < 0.01), although it had no clinical significance in the progression-free survival. HB-EGF expression was significantly correlated with ADAM 17 expression ({gamma} = 0.437, P < 0.01).

Conclusions: Our findings suggest that HB-EGF and ADAM 17 contribute to the progression of ovarian cancer and that HB-EGF plays a pivotal role in the aggressive behavior of a tumor in ovarian cancer.

Ovarian cancer is the most common cause of death from a gynecologic malignancy in most countries (1). The high mortality is predominantly due to occult progression of the tumor in the peritoneal cavity, with the initial diagnosis usually being made at an advanced stage. Currently, ~75% of ovarian cancers are diagnosed at International Federation of Gynecology and Obstetrics stages III and IV (2). Extensive dissemination of a tumor is caused by the peritoneal fluid following the circulatory pathway in the abdominal cavity, and the peritoneal fluid acts as a rich source of growth factor activity for ovarian cancer cells (3). Thus, the dissemination of cancer cells activated by ovarian cancer–activating factors results in an exaggerated increase in peritoneal fluid, which in turn leads to tumor extension in ovarian cancer. Therefore, to develop a targeting therapy, it would be extremely useful to understand the ovarian cancer–activating factor–mediated molecular mechanisms for activating ovarian cancer cells.

Lysophosphatidic acid (LPA) is a simple phospholipid with numerous cellular effects, including growth promotion, cell cycle progression, and cytoskeletal organization (4), and is generated from precursors in membranes. LPA is elevated in the plasma and peritoneal fluid from patients with ovarian cancer in all stages, suggesting that it is a possible candidate for an ovarian cancer–activating factor (5–8). In principle, LPA-induced signaling is mediated by G protein–coupled receptors, including LPA1, LPA2, LPA3, and LPA4 (4). Recent investigations have shown that G protein–coupled receptors are able to use the epidermal growth factor receptor (EGFR) as a downstream signaling partner in the generation of mitogenic signals (9), and EGFR has been recognized to play a pivotal role in the progression of ovarian cancer (10, 11). According to this evidence, it can be considered that EGFR signal transactivation induced by LPA may contribute to the promotion of a tumor in ovarian cancer.

The molecular mechanisms of EGFR signal transactivation involve processing of transmembrane growth factor precursors by metalloproteases, which have been identified as members of the ADAM (a disintegrin and metalloprotease) family of zinc-dependent proteases (9). Seven-transmembrane growth factor precursors have been described as ligands for EGFR: EGF, heparin-binding EGF-like growth factor (HB-EGF), amphiregulin, transforming growth factor-{alpha} (TGF-{alpha}), betacellulin, epiregulin, and epigen (12, 13). For the metalloproteases, there have been at least 34 adam genes described in a variety of species, and ADAM 9, 10, 12, 17, and 19, which are ubiquitously expressed in somatic tissues, have sheddase activity (14). In particular, ADAM 9, 10, 12, and 17 are involved in the ectodomain shedding of EGFR ligands (15–21). The enhancement of EGFR signal transactivation mediated by EGFR ligands and the ADAM family is linked to the pathogenesis of hyperproliferative disorders, such as cancer. Previously, we shown that HB-EGF is involved in EGFR signal transactivation induced by LPA in ovarian cancer cell lines and that the expression of HB-EGF is attributable to tumor growth on xenografted mice using ovarian cancer cell lines (22). However, no studies have yet comprehensively examined the clinical significance of EGFR ligands and ADAM family expression in human cancers.

To investigate which molecules involved in EGFR signal transactivation are associated with human ovarian cancer, we examined the expression of EGFR ligands and ADAM family members in patients with ovarian cancer, using real-time PCR, and analyzed the clinical significance of these molecules in ovarian cancer.


   Materials and Methods
Top
 Abstract
 Materials and Methods
Results
 Discussion
 References
 
Patients and surgical specimens. All 108 patients in this study had undergone surgery at the Department of Obstetrics and Gynecology, Kyushu University Hospital (Fukuoka, Japan) between January 1996 and August 2003. All the ovarian cancer specimens were obtained from 68 patients, comprising 16 cases with International Federation of Gynecology and Obstetrics stage I ovarian cancer, 10 cases with stage II, 29 cases with III, and 13 cases with stage IV. None of the patients had received chemotherapy before surgery. After dissection, half of each fresh tumor tissue specimen was immediately snap frozen in liquid nitrogen and stored at –80°C until use, whereas the other half was immediately embedded for the production of frozen or paraffin sections. Diagnosis was based on conventional morphologic examination of paraffin-embedded specimens, and tumors were classified according to the WHO classification (23). Metastases of pelvic lymph nodes in all cases and para-aortic lymph nodes in 60 cases were assessed by pathologic examination using paraffin-embedded specimens after surgery. In 8 cases, metastases of para-aortic lymph nodes were evaluated by the presence or absence of lymph node swelling in an abdominal computed tomographic scan before surgery because surgical specimens were not resected. The median follow-up periods for all patients were 30.0 months (range, 2-83 months) for overall survival and 20.0 months (range, 1-63 months) for progression-free survival. After debulking surgery, all 68 patients had platinum-based chemotherapy (median, 6.0 courses; range, 1-10 courses) as first-line chemotherapy. Normal ovarian tissue specimens were obtained at surgery for benign gynecologic disorders from 40 patients, comprising 12 premenopausal cases and 28 postmenopausal cases. Informed consent was obtained from all patients in this study.

Criteria for chemotherapy response and definition of progression-free survival interval. The response to chemotherapy induction was assessed by second-look surgery, clinical and/or radiographic evaluation according to the WHO criteria, or CA125 response using Rustin et al.'s criteria (23, 24). The progression-free interval was defined as the duration from the date at surgery to the final date observed in this study (March 31, 2004) or the duration from the date at surgery to the date when progression was diagnosed, according to the proposed definitions of progression by the Gynecologic Cancer Intergroup (25).

Preparation of RNA. To ascertain the presence of cancer cells, half of each fresh tumor tissue specimen was immediately embedded in Tissue-Tek OCT compound (Sakura, Tokyo, Japan). Frozen sections were cut on the cryostat to a thickness of 6 µm and immediately stained with H&E. More than 80% of any given tumor specimen, which contained cancer cells, were used for cDNA synthesis. RNA was extracted using TRIzol (Invitrogen Corp., Carlsbad, CA) according to the manufacturer's protocol. First-strand cDNA synthesis was done with 0.8 µg total RNA using SuperScript II reverse transcriptase (Invitrogen) following the manufacturer's protocol.

Performance of reverse transcription-PCR and real-time quantitative PCR for epidermal growth factor receptor ligands or a disintegrin and metalloprotease family members. Sense and antisense primers based on the nucleotide sequences of HB-EGF cDNA, TGF-{alpha} cDNA, amphiregulin cDNA, epiregulin cDNA, betacellulin cDNA, and EGF cDNA were used, and the PCR protocol for each EGFR ligand followed those described by Adam et al. (26) or Sorensen et al. (27). The PCR products were electrophoresed in 2% agarose gels, and the bands were visualized with ethidium bromide and photographed with a camera (Funakoshi, Tokyo, Japan). When no bands were detected, the number of amplifications was increased by 50 cycles. Real-time PCR (TaqMan PCR) was done using an ABI PRISM 7000 Sequence Detection System (Applied Biosystems, Foster City, CA) as described previously (28). The sequences of the oligonucleotide primer pairs and TaqMan probes for each EGFR ligand and ADAM family member are summarized in Table 1. Serial 1:10 dilutions of plasmid DNA containing each target cDNA (107-101 copies/µL) were analyzed and served as standard curves, from which we determined the rate of change of the threshold cycle values. The correlation coefficients of the standard curves were >0.995, thus ensuring the accuracy of our data. Plasmid DNA played the role of a positive control for each reaction. Copy numbers of the target cDNAs (HB-EGF, amphiregulin, TGF-{alpha}, epiregulin, betacellulin, ADAM 9, ADAM 10, ADAM 12, and ADAM 17) were estimated from the standard curves. All reactions for the standard and patient samples were done in triplicate, and the data were averaged from the values obtained in each reaction. To determine the mRNA levels of four EGFR ligands and four ADAM family members, we used the mRNA expression index, which is a relative mRNA expression level standardized by glyceraldehyde-3-phosphate dehydrogenase. The mRNA expression index was calculated as follows (in arbitrary units): mRNA expression index = (copy number of each EGFR ligand or each ADAM family member mRNA / copy number of glyceraldehyde-3-phosphate dehydrogenase mRNA) x 10,000 arbitrary units. When the expression index was over the maximal value in patients with normal ovaries, it was regarded as a high expression status of the molecule under analysis.


View this table:
[in this window]
[in a new window]

  		Table 1. Each oligonucleotide, probe sequence, or expression index of EGFR ligands or ADAM family in use of quantitative real-time PCR

 
In situ hybridization. In situ hybridization was done as described previously (29). Briefly, digoxigenin-labeled antisense and sense riboprobes were generated by in vitro transcription using a DIG RNA Labeling kit (SP6/T7; Roche Diagnostics GmbH, Penzberg, Germany) according to the manufacturer's instructions. The frozen samples were sectioned to a thickness of 6 µm. After fixation in 4% paraformaldehyde for 10 minutes, slides were immersed in 0.2 mol/L HCl for 10 minutes and then rinsed in phosphate buffer. Acetylation was done in 0.1 mol/L triethanolamine in 0.25% acetic anhydride for 15 minutes. After rinsing in phosphate buffer, sections were dehydrated in an ethanol gradient and dried. Sections were hybridized with the HB-EGF probe (diluted 1:10) at 55°C overnight. After high-stringency washing, the signal was visualized using an alkaline phosphatase–conjugated anti-DIG antibody (Roche Diagnostics). Three examiners (Y.T., S.M., and K.S.) separately evaluated the HB-EGF mRNA staining by cell counting. At least 20 high-magnification fields were chosen randomly, and 1,000 cells in total were counted.

Immunohistochemistry. Immunohistochemistry was done on frozen sections using a goat polyclonal antibody against HB-EGF (R&D Systems, Inc., Minneapolis, MN) and on formalin-fixed, paraffin-embedded sections using a goat polyclonal antibody against ADAM 17 (Santa Cruz Biotechnology, Inc., Santa Cruz, CA). Frozen sections were cut on a cryostat to a thickness of 6 µm, mounted on poly-L-lysine-coated slides, and either used immediately or stored at –80°C until needed. Paraffin-embedded sections were cut on a microtome to a thickness of 4 µm, mounted on poly-L-lysine-coated slides, and then dewaxed and rehydrated through xylene, graded ethanol solutions (100%, 90%, and 70%), and water. Briefly, the frozen and paraffin-embedded sections were subsequently immersed for 30 minutes in 0.3% H2O2 in absolute methanol, treated with 5% normal rabbit serum for 30 minutes, and incubated with the primary antibody against HB-EGF or ADAM 17 overnight at 4°C. The sections were then incubated with biotinylated rabbit anti-goat IgG (Nichirei Corp., Tokyo, Japan) for 30 minutes followed by an avidin-biotin-peroxidase complex solution. The peroxidase reaction was developed using 3,3'-diaminobenzidine tetrahydrochloride in the presence of 0.05% H2O2, and the sections were then counterstained in Mayer's hematoxylin, washed in tap water, dehydrated in graded ethanol, cleared in xylene, and coverslipped. Control staining was done using nonimmune goat IgG as the primary antibody. Three examiners (Y.T., S.M., and K.S.) separately evaluated the HB-EGF and ADAM 17 staining by counting the immunoreactive cells. At least 20 high-magnification fields were chosen randomly, and 1,000 cells in total were counted.

Statistical analysis. Statistical analysis was done with StatView software version 5.0 (Abacus Concepts, Berkeley, CA). The Mann-Whitney test was done to test the equality of the distribution of age and the mRNA expression index of five EGFR ligands and four ADAM family members among patients with normal ovaries, early ovarian cancer, and advanced ovarian cancer. Progression-free survival curves were estimated using the Kaplan-Meier method and analyzed by the log-rank test. Correlation between the mRNA expression indices of molecules was analyzed using Spearman's correlation analysis. Statistical significance was based on two-tailed statistical analyses, and Ps < 0.05 were considered statistically significant.


   Results
Top
 Abstract
 Materials and Methods
 Results
Discussion
 References
 
Expression of epidermal growth factor ligands in normal ovaries and ovarian cancer. Using real-time PCR, large differences in the mRNA expression index were found for HB-EGF and four other EGFR ligands between normal ovaries and ovarian cancer (Fig. 1; Table 1). For HB-EGF, the mRNA expression index was significantly elevated in advanced ovarian cancer compared with that in normal ovaries, although there was no significant difference between early ovarian cancer and normal ovaries (Fig. 1; Table 1). For TGF-{alpha}, amphiregulin, epiregulin, and betacellulin, no significant differences in the mRNA expression index were found among the three groups (Fig. 1; Table 1). No clear expression of EGF was detected in 10 patients with normal ovaries or 30 patients with ovarian cancer by reverse transcription-PCR, although EGF expression was confirmed in human placenta tissue using the same primer sets (26). Therefore, real-time PCR for EGF was not done in this study. To further investigate the expression of HB-EGF in surface normal ovarian epithelial cells, we examined the expression index of HB-EGF using 10 samples extracted by brushing normal ovarian epithelial cells. The expression index of HB-EGF mRNA was 7.6 ± 7.9 (mean ± SE), which was not significantly changed from that in samples extracted from whole normal ovaries. In a cancerous state, the expression of HB-EGF significantly increased compared with that in a normal state. These results suggest that HB-EGF contributes to the progression of ovarian cancer among the EGFR ligands.



View larger version (18K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 1. Differences in expression of EGF ligands between normal ovaries and ovarian cancer (OVCA). mRNA expression index of HB-EGF (A), TGF-{alpha} (B), amphiregulin (C), epiregulin (D), and betacellulin (E) in patients with normal ovaries, early ovarian cancer (stages I-II), and advanced ovarian cancer (stages III-IV). A line indicates the mean value of the mRNA expression index for each group. *, P < 0.05, versus patients with normal ovaries.

 
Expression of a disintegrin and metalloprotease family members in normal ovaries and ovarian cancer. A large difference in the mRNA expression index was found for ADAM 17 and three other ADAM family members in normal ovaries and ovarian cancer (Fig. 2; Table 1). For ADAM 17, the mRNA expression index in early or advanced ovarian cancer was significantly elevated compared with that in normal ovaries, and there was no significant difference between early and advanced ovarian cancers (Fig. 2; Table 1). For ADAM 9, 10, and 12, no significant differences in the mRNA expression index were found among the three groups (Fig. 2; Table 1). To further investigate the expression of ADAM 17 in normal surface ovarian epithelial cells, we examined the expression index of ADAM 17 using 10 samples extracted by brushing normal ovarian epithelial cells. The expression index of ADAM 17 mRNA was 440 ± 380 (mean ± SE), which was not significantly changed from that in samples extracted from whole normal ovaries. In a cancerous state, the expression of ADAM 17 significantly increased compared with that in a normal state. Taken together, these results suggest that ADAM 17 is involved in the occurrence of ovarian cancer.



View larger version (26K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 2. Differences in expression of ADAM family members in normal ovaries and ovarian cancer. mRNA expression index of ADAM 17 (A), ADAM 9 (B), ADAM 10 (C), and ADAM 12 (D) in patients with normal ovaries, early ovarian cancer (stages I-II), and advanced ovarian cancer (stages III-IV). A line indicates the mean value of the mRNA expression index for each group. **, P < 0.01, versus patients with normal ovaries.

 
Clinical significance of heparin-binding epidermal growth factor–like growth factor or a disintegrin and metalloprotease 17 expression in ovarian cancer. HB-EGF expression ranged from a mRNA expression index of 10 to 39 in patients with normal ovaries. Ovarian cancer patients with a HB-EGF mRNA expression index of >40 were therefore regarded as cases with a high expression status of HB-EGF. In the progression-free survival curves, ovarian cancer patients with a high expression status of HB-EGF showed a significantly less favorable prognosis than those with a low expression status (Fig. 3A). Taken together, these results suggest that HB-EGF plays a significant role in the progression of ovarian cancer. ADAM 17 expression was within a mRNA expression index of 999 in patients with normal ovaries. Ovarian cancer patients with an ADAM 17 mRNA expression index of >1,000 were therefore regarded as cases with a high expression status of ADAM 17. No significant difference in the progression-free survival curves was found between ovarian cancer patients with a low and high expression status of ADAM 17 (Fig. 3B), suggesting that ADAM 17 is not significantly associated with the clinical outcome.



View larger version (20K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 3. Clinical significance of HB-EGF and ADAM 17 expression in ovarian cancer. Progression-free survival of 68 patients with ovarian cancer in relation to the tumor HB-EGF expression status (A) and tumor ADAM 17 expression status (B). Ps were determined using the log-rank test.

 
Relationships between the expression indices of heparin-binding epidermal growth factor–like growth factor and a disintegrin and metalloprotease family members in ovarian cancer. Significant correlations were found between the mRNA expression indices for HB-EGF and ADAM 9, 12, and 17 (Fig. 4A, B, and D). The mRNA expression index of ADAM 10 showed no significant correlation with that of HB-EGF in ovarian cancer (Fig. 4C). The correlation coefficient between the mRNA expression index of HB-EGF and that of ADAM 17 was increased compared with those between HB-EGF and ADAM 9 or 12, suggesting that ADAM 17 has a more significant contribution to the ectodomain shedding of HB-EGF than ADAM 9 or 12.



View larger version (29K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 4. Spearman's correlations between the mRNA expression indices of HB-EGF and ADAM family members in patients with ovarian cancer. The ordinate and abscissas indicate the mRNA expression index of HB-EGF and ADAM 17 (A), ADAM 9 (B), ADAM 10 (C), and ADAM 12 (D), respectively, in patients with ovarian cancer. {gamma} indicates the Spearman's correlation coefficient.

 
Localization of heparin-binding epidermal growth factor–like growth factor and a disintegrin and metalloprotease 17 proteins in normal ovarian epithelial cells and ovarian cancer cells. Abundant HB-EGF protein appeared as positive in interstitial tissues surrounding the ovarian cancer cells, whereas no definite expression of HB-EGF was observed in normal ovarian epithelial cells or interstitial tissues (Fig. 5A and B). In in situ hybridization, diffuse staining for HB-EGF mRNA was only found in ovarian cancer cells and not in either interstitial cells surrounding the cancer cells or normal ovarian epithelial cells (Fig. 5C and D), suggesting that HB-EGF protein is only produced by cancer cells, and not by interstitial cells, and that the proteolytic form of HB-EGF accumulates in the extracellular matrix with heparin sulfate in the interstitial tissues surrounding the cancer cells. The correlation coefficient between the mRNA expression index of HB-EGF and the in situ hybridization score of HB-EGF was 0.876 in ovarian cancer (P < 0.001). In addition, positive staining for ADAM 17 was observed in cancer cells, whereas no cells showed positive expression of ADAM 17 in normal ovarian epithelium (Fig. 5E and F). In ovarian cancer, the correlation coefficient between the ADAM 17 immunostaining and the mRNA expression index of ADAM 17 was 0.839 (P < 0.01).



View larger version (107K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 5. Immunohistochemical staining and in situ hybridization of HB-EGF. No definite expression of HB-EGF protein (A) or mRNA (C) is present in a patient with normal ovaries. In a patient with advanced ovarian cancer, positive immunostaining of HB-EGF is observed in interstitial tissues surrounding the cancer cells and in some of the cancer cells (B). Diffuse staining of HB-EGF mRNA is only detected in the cytoplasm of cancer cells by in situ hybridization (D). No clear expression of ADAM 17 protein is found in a patient with normal ovaries (E). In a patient with advanced ovarian cancer, positive immunostaining of ADAM 17 is observed in cancer cells (F). Original magnification, x200. Insets, higher-magnification view (x400).

 

   Discussion
Top
 Abstract
 Materials and Methods
 Results
 Discussion
References
 
Impairment of the EGF system is involved in the pathogenesis of different types of carcinomas (10, 11). Univariate and multivariate statistical analyses have confirmed that EGFR overexpression is significantly associated with a high risk of progression in ovarian cancer patients (30). Relatively high frequencies of TGF-{alpha} and amphiregulin have been described in ovarian carcinomas, although the staining varied from weak to strong in tumors (31, 32). Ovarian cancer cells are sensitive to the diphtheria toxin, indicating the expression of pro-HB-EGF (33). No significant expression of EGF is present in normal ovaries or ovarian cancer. Thus, it remained unclear which EGFR ligands were predominantly expressed in ovarian cancer. In this study, however, abundant expression of HB-EGF was found in ovarian cancer compared with other EGFR ligands. Recently, several studies have revealed that HB-EGF is involved in a variety of cancers. In bladder cancer, HB-EGF is abundantly expressed and a significant prognostic marker for survival (34). HB-EGF expression is also associated with the clinical outcome in gastric, pancreatic, and breast cancers, in which HB-EGF expression is markedly abundant (35–37). In addition, Helicobacter pylori infection in human gastric carcinogenesis and the inflammatory processes associated with this type of infection have been linked to HB-EGF-dependent EGFR signal transactivation in human gastric epithelial tumor cells (38, 39). According to these studies, HB-EGF has been implicated in the occurrence and progression of human cancers. In this study, HB-EGF expression was significantly associated with the clinical outcome in ovarian cancer, suggesting that HB-EGF plays a crucial role in the aggressive behavior of a tumor in ovarian cancer.

The ADAM family has been implicated in diverse processes, including membrane fusion, cytokine and growth factor shedding, and cell migration (14). In particular, recent findings have revealed that the ADAM family is involved in cancer. ADAM 9 expression is associated with the clinical significance of human breast and pancreatic cancers (40, 41), whereas abundant ADAM 17 protein is expressed in human breast cancer (42). In human gastric carcinoma, high levels of transcripts for ADAM 10, 17, and 20 are present (43), whereas, in human liver cancer, expression of ADAM 9 and 12 is associated with tumor aggressiveness and progression (44). Thus, a few members of the ADAM family may be simultaneously associated with the acceleration and progression of human cancers. Therefore, any ADAM family members with similar functions should be examined to identify those involved in the pathogenesis of cancer. In this study, the expression of each ADAM family member involved in the ectodomain shedding of HB-EGF (15–21) was quantitatively estimated in human ovarian cancer. ADAM 17 was abundantly expressed compared with the other three ADAM family members, and its expression was enhanced in ovarian cancer. Therefore, this elevation of ADAM 17 expression in cancer might facilitate the proteolytic cleavage of EGFR ligands that are involved in the progression of cancer.

LPA can mediate EGFR signal transactivation through different combinations of EGFR ligands and ADAM family members. In NCI-H292 lung cancer cells, LPA transactivates EGFR through the ectodomain shedding of HB-EGF or amphiregulin, which is cleaved by ADAM 17 (45). In kidney cancer cells, EGFR transactivation is mediated by LPA, in association with HB-EGF and ADAM 10 or 17 (46). In bladder cancer cells, ADAM 15 has a role in EGFR transactivation mediated by LPA via soluble forms of amphiregulin or TGF-{alpha} (46). Thus, in the same cell system, there is a functional redundancy between EGFR ligands and ADAM family members that depends on a variety of stimuli. In ovarian cancer cells, HB-EGF and ADAM 17 were abundantly expressed compared with other EGFR ligands and other members of the ADAM family, respectively, and LPA activated EGFR through the ectodomain shedding of HB-EGF (22). In this study, the expressions of both HB-EGF and ADAM 17 were also abundant compared with those of other EGFR ligands and other members of the ADAM family in human ovarian cancer. In addition, HB-EGF protein appeared to accumulate in the interstitial tissues surrounding cancer cells and abundant ADAM 17 was also expressed in cancer cells, leading to the speculation that most HB-EGF expressed in cancer cells is quickly cleaved by ADAM 17. In fact, a large amount of HB-EGF was observed in the peritoneal fluid of ovarian cancer patients compared with the levels of amphiregulin and TGF-{alpha} (22). Taken together, these results suggest that proteolytic cleavage of HB-EGF was extensively provoked by ADAM 17 in human ovarian cancer.

This is the first study to show that both HB-EGF and ADAM 17 are significantly expressed among EGFR ligands and ADAM family members in human ovarian cancer. We have shown that tumor formation of ovarian cancer was completely blocked by pro-HB-EGF gene RNA interference and that the release of soluble HB-EGF is essential for tumor formation (22). Therefore, the development of therapeutic tools against HB-EGF and ADAM 17 would allow us to explore novel targeting therapy to human ovarian cancer.


   Acknowledgments
 
We thank E. Hori and Y. Kubota for technical assistance and L. Saza and Drs. H. Baba, R. Tsunematsu, M. Tsuneyoshi, K. Sueishi, and T. Iwaki for critical comments.


   Footnotes
 
Grant support: Ministry of Health and Welfare of Japan Grant-in-Aid for Cancer Research 16591667 (S. Miyamoto) and Ministry of Education, Culture, Sports, Science and Technology Grant-in-aid for Scientific Research on Priority Areas 14032202 (E. Mekada).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received 7/21/04; revised 12/ 7/04; accepted 12/15/04.


   References
Top
 Abstract
 Materials and Methods
 Results
 Discussion
 References
 

  1. Penson RT, Shannon KE, Sharpless NE, Seiden MV. Ovarian cancer: an update on genetics and therapy. Compr Ther 1998;24:477–87.[Medline]
  2. Friedlander ML. Prognostic factors in ovarian cancer. Semin Oncol 1998;25:305–14.[Medline]
  3. Mills GB, May C, McGill M, Roifman CM, Mellors A. A putative new growth factor in ascitic fluid from ovarian cancer patients: identification, characterization, and mechanism of action. Cancer Res 1988;48:1066–71.[Abstract/Free Full Text]
  4. Mills GB, Moolenaar WH. The emerging role of lysophosphatidic acid in cancer. Nat Rev Cancer 2003;3:582–91.[CrossRef][Medline]
  5. Xu Y, Gaudette DC, Boynton JD, et al. Characterization of an ovarian cancer activating factor in ascites from ovarian cancer patients. Clin Cancer Res 1995;1:1223–32.[Abstract]
  6. Westermann AM, Havik E, Postma FR, et al. Malignant effusions contain lysophosphatidic acid (LPA)-like activity. Ann Oncol 1998;9:437–42.[Abstract/Free Full Text]
  7. Xiao YJ, Schwartz B, Washington M, et al. Electrospray ionization mass spectrometry analysis of lysophospholipids in human ascitic fluids: comparison of the lysophospholipid contents in malignant vs nonmalignant ascitic fluids. Anal Biochem 2001;290:302–13.[CrossRef][Medline]
  8. Xu Y, Shen Z, Wiper DW, et al. Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers. JAMA 1998;280:719–23.[Abstract/Free Full Text]
  9. Fischer OM, Hart S, Gschwind A, Ullrich A. EGFR signal transactivation in cancer cells. Biochem Soc Trans 2003;31:1203–8.[Medline]
  10. Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995;19:183–232.[Medline]
  11. Normanno N, Bianco C, De Luca A, Maiello MR, Salomon DS. Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment. Endocr Relat Cancer 2003;10:1–21.[Abstract]
  12. Riese DJ II, Stern DF. Specificity within the EGF family/ErbB receptor family signaling network. Bioessays 1998;20:41–8.[CrossRef][Medline]
  13. Strachan L, Murison JG, Prestidge RL, Sleeman MA, Watson JD, Kumble KD. Cloning and biological activity of epigen, a novel member of the epidermal growth factor superfamily. J Biol Chem 2001;276:18265–71.[Abstract/Free Full Text]
  14. Seals DF, Courtneidge SA. The ADAMs family of metalloproteases: multidomain proteins with multiple functions. Genes Dev 2003;17:7–30.[Free Full Text]
  15. Sunnarborg SW, Hinkle CL, Stevenson M, et al. Tumor necrosis factor-{alpha} converting enzyme (TACE) regulates epidermal growth factor receptor ligand availability. J Biol Chem 2002;277:12838–45.[Abstract/Free Full Text]
  16. Sahin U, Weskamp G, Kelly K, et al. Distinct roles for ADAM10 and ADAM17 in ectodomain shedding of six EGFR ligands. J Cell Biol 2004;164:769–79.[Abstract/Free Full Text]
  17. Izumi Y, Hirata M, Hasuwa H, et al. A metalloprotease-disintegrin, MDC9/meltrin-{gamma}/ADAM9 and PKC{delta} are involved in TPA-induced ectodomain shedding of membrane-anchored heparin-binding EGF-like growth factor. EMBO J 1998;17:7260–72.[CrossRef][Medline]
  18. Umata T, Hirata M, Takahashi T, et al. A dual signaling cascade that regulates the ectodomain shedding of heparin-binding epidermal growth factor-like growth factor. J Biol Chem 2001;276:30475–82.[Abstract/Free Full Text]
  19. Lemjabbar H, Basbaum C. Platelet-activating factor receptor and ADAM10 mediate responses to Staphylococcus aureus in epithelial cells. Nat Med 2002;8:41–6.[CrossRef][Medline]
  20. Yan Y, Shirakabe K, Werb Z. The metalloprotease Kuzbanian (ADAM10) mediates the transactivation of EGF receptor by G protein-coupled receptors. J Cell Biol 2002;158:221–6.[Abstract/Free Full Text]
  21. Asakura M, Kitakaze M, Takashima S, et al. Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: metalloproteinase inhibitors as a new therapy. Nat Med 2002;8:35–40.[CrossRef][Medline]
  22. Miyamoto S, Hirata M, Yamazaki A, et al. Heparin-binding EGF-like growth factor and the LPA-induced ectodomain shedding pathway is a promising target for the therapy of ovarian cancer. Cancer Res 2004;64:5720–7.[Abstract/Free Full Text]
  23. WHO. WHO handbook for reporting results of cancer treatment. WHO Offset Publ 1979;48:5–45.
  24. Rustin GJ, Nelstrop AE, McClean P, et al. Defining response of ovarian carcinoma to initial chemotherapy according to serum CA125. J Clin Oncol 1996;14:1545–51.[Abstract/Free Full Text]
  25. Vergote I, Rustin GJ, Eisenhauer EA, et al. Re: New guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. Gynecologic Cancer Intergroup. J Natl Cancer Inst 2000;92:1534–5.[Free Full Text]
  26. Adam RM, Borer JG, Williams J, Eastham JA, Loughlin KR, Freeman MR. Amphiregulin is coordinately expressed with heparin-binding epidermal growth factor-like growth factor in the interstitial smooth muscle of the human prostate. Endocrinology 1999;140:5866–75.[Abstract/Free Full Text]
  27. Sorensen BS, Torring N, Bor MV, Nexo E. Quantitation of the mRNA expression of the epidermal growth factor system: selective induction of heparin-binding epidermal growth factor-like growth factor and amphiregulin expression by growth factor stimulation of prostate stromal cells. J Lab Clin Med 2000;20:91–5.
  28. Ohishi Y, Oda Y, Uchiumi T, et al. ATP-binding cassette superfamily transporter gene expression in human primary ovarian carcinoma. Clin Cancer Res 2002;8:3767–75.[Abstract/Free Full Text]
  29. Suzuki SO, Iwaki T. Non-isotopic in situ hybridization of CD44 transcript in formalin-fixed paraffin-embedded sections. Brain Res Protoc 1999;4:29–35.[CrossRef][Medline]
  30. Scambia G, Benedetti Panici P, Battaglia F, et al. Significance of epidermal growth factor receptor in advanced ovarian cancer. J Clin Oncol 1992;10:529–35.[Abstract/Free Full Text]
  31. Morishige K, Kurachi H, Amemiya K, et al. Evidence for the involvement of transforming growth factor {alpha} and epidermal growth factor receptor autocrine growth mechanism in primary human ovarian cancers in vitro. Cancer Res 1991;51:5322–8.[Abstract/Free Full Text]
  32. D'Antonio A, Losito S, Pignata S, et al. Transforming growth factor {alpha}, amphiregulin and cripto-1 are frequently expressed in advanced human ovarian carcinomas. Int J Oncol 2002;21:941–8.[Medline]
  33. Morimoto H, Safrit JT, Bonavida B. Synergistic effect of tumor necrosis factor-{alpha}- and diphtheria toxin-mediated cytotoxicity in sensitive and resistant human ovarian tumor cell lines. J Immunol 1991;147:2609–16.[Abstract/Free Full Text]
  34. Thogersen VB, Sorensen BS, Poulsen SS, Orntoft TF, Wolf H, Nexo E. A subclass of HER1 ligands are prognostic markers for survival in bladder cancer patients. Cancer Res 2001;61:6227–33.[Abstract/Free Full Text]
  35. Kobrin MS, Funatomi H, Friess H, Buchler MW, Stathis P, Korc M. Induction and expression of heparin-binding EGF-like growth factor in human pancreatic cancer. Biochem Biophys Res Commun 1994;202:1705–9.[CrossRef][Medline]
  36. Ito Y, Takeda T, Higashiyama S, Noguchi S, Matsuura N. Expression of heparin-binding epidermal growth factor-like growth factor in breast carcinoma. Breast Cancer Res Treat 2001;67:81–5.[CrossRef][Medline]
  37. Murayama Y, Miyagawa J, Shinomura Y, et al. Significance of the association between heparin-binding epidermal growth factor-like growth factor and CD9 in human gastric cancer. Int J Cancer 2002;98:505–13.[CrossRef][Medline]
  38. Romano M, Ricci V, Di Popolo A, et al. Helicobacter pylori upregulates expression of epidermal growth factor-related peptides, but inhibits their proliferative effect in MKN28 gastric mucosal cells. J Clin Invest 1998;101:1604–13.[Medline]
  39. Wallasch C, Crabtree JE, Bevec D, Robinson PA, Wagner H, Ullrich A. Helicobacter pylori-stimulated EGF receptor transactivation requires metalloprotease cleavage of HB-EGF. Biochem Biophys Res Commun 2002;295:695–701.[CrossRef][Medline]
  40. O'Shea C, McKie N, Buggy Y, et al. Expression of ADAM-9 mRNA and protein in human breast cancer. Int J Cancer 2003;105:754–61.[CrossRef][Medline]
  41. Grutzmann R, Luttges J, Sipos B, et al. ADAM9 expression in pancreatic cancer is associated with tumour type and is a prognostic factor in ductal adenocarcinoma. Br J Cancer 2004;90:1053–8.[CrossRef][Medline]
  42. Borrell-Pages M, Rojo F, Albanell J, Baselga J, Arribas J. TACE is required for the activation of the EGFR by TGF-{alpha} in tumors. EMBO J 2003;22:1114–24.[CrossRef][Medline]
  43. Yoshimura T, Tomita T, Dixon MF, Axon AT, Robinson PA, Crabtree JE. ADAMs (a disintegrin and metalloproteinase) messenger RNA expression in Helicobacter pylori-infected, normal, and neoplastic gastric mucosa. J Infect Dis 2002;185:332–40.[CrossRef][Medline]
  44. Le Pabic H, Bonnier D, Wewer UM, et al. ADAM12 in human liver cancers: TGF-ß-regulated expression in stellate cells is associated with matrix remodeling. Hepatology 2003;37:1056–66.[CrossRef][Medline]
  45. Hart S, Fischer OM, Ullrich A. Cannabinoids induce cancer cell proliferation via tumor necrosis factor {alpha}-converting enzyme (TACE/ADAM17)-mediated transactivation of the epidermal growth factor receptor. Cancer Res 2004;64:1943–50.[Abstract/Free Full Text]
  46. Schafer B, Gschwind A, Ullrich A. Multiple G-protein-coupled receptor signals converge on the epidermal growth factor receptor to promote migration and invasion. Oncogene 2004;23:991–9.[CrossRef][Medline]



This article has been cited by other articles:


Home page
 Anticancer ResHome page
S. MIYAMOTO, T. FUKAMI, H. YAGI, M. KUROKI, and F. YOTSUMOTO
Potential for Molecularly Targeted Therapy against Epidermal Growth Factor Receptor Ligands
Anticancer Res, March 1, 2009; 29(3): 823 - 830.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
J. P. Edwards, X. Zhang, and D. M. Mosser
The Expression of Heparin-Binding Epidermal Growth Factor-Like Growth Factor by Regulatory Macrophages
J. Immunol., February 15, 2009; 182(4): 1929 - 1939.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
J. Sarup, P. Jin, L. Turin, X. Bai, M. Beryt, C. Brdlik, J. N. Higaki, B. Jorgensen, F. W. Lau, P. Lindley, et al.
Human epidermal growth factor receptor (HER-1:HER-3) Fc-mediated heterodimer has broad antiproliferative activity in vitro and in human tumor xenografts
Mol. Cancer Ther., October 1, 2008; 7(10): 3223 - 3236.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
H. Yagi, F. Yotsumoto, and S. Miyamoto
Heparin-binding epidermal growth factor-like growth factor promotes transcoelomic metastasis in ovarian cancer through epithelial-mesenchymal transition
Mol. Cancer Ther., October 1, 2008; 7(10): 3441 - 3451.
[Abstract] [Full Text] [PDF]

Home page
 J BiochemHome page
T. Kageyama, M. Ohishi, S. Miyamoto, H. Mizushima, R. Iwamoto, and E. Mekada
Diphtheria Toxin Mutant CRM197 Possesses Weak EF2-ADP-ribosyl Activity that Potentiates its Anti-tumorigenic Activity
J. Biochem., July 1, 2007; 142(1): 95 - 104.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. M. McGowan, B. M. Ryan, A. D.K. Hill, E. McDermott, N. O'Higgins, and M. J. Duffy
ADAM-17 Expression in Breast Cancer Correlates with Variables of Tumor Progression
Clin. Cancer Res., April 15, 2007; 13(8): 2335 - 2343.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
B. Santiago-Josefat, C. Esselens, J. J. Bech-Serra, and J. Arribas
Post-transcriptional Up-regulation of ADAM17 upon Epidermal Growth Factor Receptor Activation and in Breast Tumors
J. Biol. Chem., March 16, 2007; 282(11): 8325 - 8331.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
E. Nishi, Y. Hiraoka, K. Yoshida, K. Okawa, and T. Kita
Nardilysin Enhances Ectodomain Shedding of Heparin-binding Epidermal Growth Factor-like Growth Factor through Activation of Tumor Necrosis Factor-{alpha}-converting Enzyme
J. Biol. Chem., October 13, 2006; 281(41): 31164 - 31172.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tanaka, Y.
Right arrow Articles by Nakano, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tanaka, Y.
Right arrow Articles by Nakano, H.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online